Clinical trials: Acute Distress Respiratory
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Acute Respiratory Distress Syndrome
Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)
With this study researchers want to find the highest safe dose of the soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 and how safe and well the study drug works.
- Trial name
- NCT04609943
- Testing
- BAY1211163
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Bayer
Acute Respiratory Distress Syndrome
To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
To evaluate the safety and initial efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome.
- Trial name
- NCT06038916
- Testing
- STSA-1002 Injection
- Where
- 30 sites in China
- Volunteers
- 47 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Acute Respiratory Distress Syndrome, Acute Kidney Injury
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane.
- Trial name
- SPARE (NCT07326215)
- Testing
- PrismaLung+, Invasive Mechanical Ventilation
- Where
- 10 sites in China
- Volunteers
- 99 people
- Sponsor
- Vantive Health LLC
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress…
- Trial name
- NCT04905836
- Testing
- COVI-MSC
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sorrento Therapeutics, Inc.
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
COVID-19
Efficacy of KOVIR Capsule in the Combination Regimen With Background Treatment in COVID-19 Patients
The acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as COVID-19 by the World Health Organization (WHO), is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05044650
- Testing
- KOVIR capsule combined with background treatment
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- Sao Thai Duong Joint Stock Company
Acute Respiratory Distress Syndrome (ARDS)
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome
- Trial name
- NCT07208591
- Testing
- STSA-1002 injection
- Where
- 15 sites in China
- Volunteers
- 406 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Respiratory Insufficiency
Description of Fluid Balance in Patients With Acute Respiratory Failure
The specific aim of this study is to gather data on fluid balance, intravenous medication administration, electrolyte balance, and diuretic and dialysis use in patients with acute respiratory failure who might benefit from a…
- Trial name
- NCT02523872
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Smiths Medical, ASD, Inc.
COVID-19, Acute Respiratory Distress Syndrome
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite
This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
- Trial name
- NCT04401527
- Testing
- Sodium Nitrite, Normal Saline
- Where
- 2 sites in United States
- Sponsor
- Hope Pharmaceuticals
COVID-19
Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- KOVIR (NCT05042141)
- Testing
- KOVIR oral capsule
- Where
- Vietnam
- Volunteers
- 66 people
- Sponsor
- Sao Thai Duong Joint Stock Company
COVID-19 Pneumonia, Acute Respiratory Distress Syndrome
Respiratory COVID-19: A Randomized, Sham-Controlled Study
A study of intubated critically ill patients infected with SARS-COV-2 to evaluate the safety and treatment effects of ultraviolet-A (UVA) light administered by a novel device via endotracheal tube in a first-in-human study.
- Conditions
- COVID-19 Pneumonia, Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Respiratory Infection
- Trial name
- NCT05166915
- Testing
- UVA Light Emitting Catheter
- Where
- 2 sites in Spain
- Sponsor
- Aytu BioPharma, Inc.
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes.
- Trial name
- NCT05387278
- Testing
- EV-Pure™ and WJ-Pure™
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vitti Labs, LLC
Acute Respiratory Distress Syndrome
Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)
The clinical study with UMC119-06 is designed to investigate the safety in patients with moderate acute respiratory distress syndrome ("ARDS"). This will be a dose escalation, open-label, single-center study in adult with ARDS.
- Trial name
- NCT04347967
- Testing
- UMC119-06
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Meridigen Biotech Co., Ltd.
Respiratory Distress Syndrome, Acute
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis.
- Trial name
- NCT05795465
- Testing
- GEn-1124
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- GEn1E Lifesciences
Acute Respiratory Distress Syndrome
Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome
The goal of this clinical trial is to explore the safety, tolerability, and efficacy in study intervention, MatriPlax, in subjects with Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT05886985
- Testing
- MatriPlax
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- BioSpring Medical Co., Ltd
Lung Injury, Acute and Respiratory Distress Syndrome, Adult
Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery
Lung injury in patients undergoing oesophagectomy may occur during surgery (peri-operatively) as a result of One Lung Ventilation (OLV) and/or during the immediate post-operative period when patients receive intensive care.
- Trial name
- NCT02221037
- Testing
- GSK2862277
- Where
- 6 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline